Molbio Diagnostics Achieves WHO-IARC Validation for Truenat HPV-HR Plus, a Global First

For Indian biotech manufacturers tracking global market access, Molbio Diagnostics' Truenat HPV-HR Plus has cleared a regulatory threshold that carries direct parallels to pharma approval pathways: formal validation by WHO-IARC, making it the world's first reduced-valency HPV DNA test to meet that standard.

The Truenat HPV-HR Plus is a point-of-care molecular diagnostic designed for cervical cancer screening. Its WHO-IARC validation confirms analytical and clinical performance against internationally accepted benchmarks, a process structurally similar to the dossier-based technical reviews that govern in vitro diagnostic approvals under frameworks such as the EU IVDR or US 21 CFR Part 820. For QA and regulatory leads at Indian diagnostics and biotech firms, the validation pathway Molbio navigated offers a working reference for how indigenous platforms can be positioned for WHO prequalification and, by extension, procurement by global health agencies.

The reduced-valency design targets the high-risk HPV genotypes most associated with cervical carcinoma, allowing a streamlined assay without sacrificing clinical sensitivity against full-valency comparators. That trade-off, scope versus performance, is precisely the kind of risk-benefit documentation that regulatory bodies scrutinize during technical review, whether the submission is for a diagnostic, a biologic, or a combination product. Molbio's successful navigation of the WHO-IARC process suggests its analytical validation package was sufficiently robust to withstand that level of scrutiny.

India's cervical cancer burden remains among the highest globally, and the government's national screening agenda has accelerated demand for decentralized, affordable HPV testing. Truenat's cartridge-based, near-patient format aligns with that infrastructure requirement. For manufacturers watching this space, the commercial and regulatory signal is consistent: indigenous platforms validated against WHO standards carry stronger procurement credentials in low- and middle-income country markets than those relying solely on national regulatory clearance.

The next measurable checkpoint is whether Molbio pursues formal WHO prequalification for Truenat HPV-HR Plus, a step that would open procurement channels through UNICEF, PAHO, and the Global Fund and serve as a replicable model for other Indian biotech firms targeting global diagnostics markets.

Source: Media4Growth via Indian Pharma Post, 12 June 2026.